Inclusion Criteria:

          1. Phase 1b part only: Participants with advanced, nonresectable, or recurrent solid
             tumor for which no alternative standard therapy or no effective therapy exists
             (participants who will be the candidate of treatment by nivolumab monotherapy as
             standard therapy is acceptable)

          2. Phase 2 part only: Nonresectable specific solid tumor participants with confirmed
             diagnosis who showed disease progression by investigator's assessment during or after
             1st line chemotherapy and did not receive any other systemic chemotherapy to
             advanced/recurrent disease

          3. Participants who have accessible tumors for biopsy and agree with tumor biopsy for pre
             and post treatment of study drug (If a pre-treatment biopsy cannot be obtained due to
             safety issue, then an archival tumor tissue sample may be submitted)

          4. Life expectancy of greater than or equal to (>=) 12 weeks

          5. Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) 0-1

          6. Phase 2 part only: At least one measurable lesion based on RECIST 1.1 (Lesions that
             have had radiotherapy or loco-regional therapies must show evidence of progressive
             disease to be deemed a measurable lesion)

        Exclusion Criteria:

          1. Diagnosed with meningeal carcinomatosis

          2. Participants with brain or subdural metastases or invasion are not eligible

          3. Participants with any active, known, or suspected autoimmune disease